Search Results
Jun 12, 2026, 12:50 ET PICS CLASS ACTION ALERT: Johnson Fistel Encourages PicS N.V. Shareholders to Submit Their Information Before August 4, 2026 Lead Plaintiff Deadline
exposures previously classified as Stage 2 to Stage 3, leading to an incremental ECL charge of R$88 million in the three months ended December 31, 2025; (iii) PicS N.V. had experienced a heightened, but unreported, Stage 3 formation rate of more than 7% in the fourth quarter of 2025 that deviated substantially
More news about: Johnson Fistel, PLLP
Jun 12, 2026, 09:00 ET "Be The People" Releases Song "Gotta Be Us (Be The People)," a New Anthem Inviting Americans to Show Up and Solve Problems in Their Communities
Atlanta Changemakers, a citywide initiative celebrating local leaders including National Leadership Council members Martin Luther King III and Arndrea Waters King for making a difference in their community. Hundreds of nominations were submitted, culminating in Atlanta educator Mikal Driver
More news about: Be The People
Jun 12, 2026, 09:00 ET Braeburn to Present Research at CPDD 2026 Annual Meeting, Including Data on Withdrawal Suppression and Real-World Treatment Retention in Patients With Opioid Use Disorder
solution for injection.WARNINGS AND PRECAUTIONSAddiction, Abuse, and Misuse: BRIXADI contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject
More news about: Braeburn
Jun 12, 2026, 08:00 ET Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
investigational ultra-long-acting once-weekly basal insulin analog independently developed by Gan & Lee Pharmaceuticals. The drug's pivotal Phase III clinical trial in China, SUPER-3, recently met its pre-specified primary endpoint.SUPER-3 is a 26-week, treat-to-target, Phase 3 clinical trial
More news about: Gan & Lee Pharmaceuticals
Jun 12, 2026, 07:22 ET Natural Grocers® Celebrates Arkansas Day with a Special Gift and Savings June 15-17, 2026
details via {N}power email or app. Must present phone number at checkout to accumulate towards the minimum requirement in one transaction.[iii] Sign up by 6/13/2026 to receive this coupon via email or app. {N}power offers are available only to registered members and are subject to program
More news about: Natural Grocers by Vitamin Cottage, Inc.
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Clinicaltrials.gov. NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil
More news about: AbbVie
Jun 12, 2026, 03:00 ET AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Clinicaltrials.gov. NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil
More news about: AbbVie
Jun 11, 2026, 21:57 ET Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies. Study results demonstrate gumokimab's rapid and robust efficacy, durable complete skin clearance,
More news about: Akeso, Inc.
Jun 11, 2026, 19:05 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines - GRAL
information about joining the class action]On February 19, 2026, Grail announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail attributed this shortcoming, in part, to "probably need[ing] a longer follow-up time to
More news about: Pomerantz LLP
Jun 11, 2026, 19:05 ET Pomerantz Law Firm Announces the Filing of a Class Action Against BitGo Holdings, Inc. and Certain Officers - BTGO
Defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Pomerantz LLP
Jun 11, 2026, 18:15 ET Toby Neugebauer Files Definitive Proxy Solicitation Materials to Put Fermi's Future in Shareholder Hands
beneficially owns 44,656,376 shares of Common Stock, (ii) 94,359,659 shares of Common Stock beneficially owned by Melissa A. Neugebauer 2020 Trust, and (iii) 7,500,000 shares of Common Stock underlying restricted stock units held by Mr. Neugebauer that vested in connection with his termination without cause.
More news about: Toby Neugebauer
Jun 11, 2026, 16:50 ET Toby Neugebauer Files Definitive Proxy Solicitation Materials to Put Fermi's Future in Shareholder Hands
beneficially owns 44,656,376 shares of Common Stock, (ii) 94,359,659 shares of Common Stock beneficially owned by Melissa A. Neugebauer 2020 Trust, and (iii) 7,500,000 shares of Common Stock underlying restricted stock units held by Mr. Neugebauer that vested in connection with his termination without cause.
More news about: Toby Neugebauer
Jun 11, 2026, 16:45 ET Hut 8 Names E. Stanley O'Neal Chair of the Board
70,370,263Mayo A. Shattuck III 63,437,474
More news about: Hut 8 Corp.
Jun 11, 2026, 16:36 ET BTGO Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against BitGo Holdings, Inc.
defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Robbins LLP
Jun 11, 2026, 16:15 ET Hyperscale Data Confirms Production of First 30 Omnipresent Robotics OPR-R2 Humanoid Robots Has Begun
commercialization."We believe that physical AI is an incredibly important aspect in the future of artificial intelligence," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "While today's leading AI models excel at reasoning, language, and content generation, tomorrow's AI systems
More news about: Hyperscale Data Inc.
Jun 11, 2026, 15:15 ET ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit
ADMA Biologics engaged in an undisclosed related party transaction; (ii) ADMA Biologics used channel stuffing to create an appearance of revenue; and (iii) ADMA Biologics lacked adequate internal controls.On March 24, 2026, Culper Research issued a report entitled "ADMA Biologics Inc (ADMA): Channel
More news about: Robbins Geller Rudman & Dowd LLP
Jun 11, 2026, 13:25 ET World Fire Congress advances global fire service collaboration through new Secretariat and research framework
challenges."It is an honor for the Metropolitan Fire Chiefs Association to serve as the Secretariat for the World Fire Congress," said Otto Drozd III, Executive Secretary of Metro Chiefs. "What is being established through this partnership is far more than operational coordination for a single event.
More news about: National Fire Protection Association, Inc.
Jun 11, 2026, 13:15 ET 208 Greenberg Traurig Attorneys, 52 Practices Recognized in The Legal 500 United States 2026 Edition
John D. Owens, IIIM&A/Corporate and Commercial – Venture Capital
More news about: Greenberg Traurig, LLP
Jun 11, 2026, 12:28 ET Gallatin AI Awarded Contract by US Army's III Armored Corps
/PRNewswire/ -- Gallatin AI today announced it has been awarded a contract by the US Army's III Armored Corps to deploy and refine Navigator, its AI-native logistics decision support suite, in direct support of III Corps exercises and operational planning over the next 18 months.
More news about: Gallatin AI
Jun 11, 2026, 12:00 ET Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
that:Defendants misrepresented the likelihood of achieving the primary endpoint of a statistically significant reduction in Stage III–IV cancers in Grail's NHS-Galleri trial, creating the false impression that they possessed reliable information supporting such outcome while concealing
More news about: Bronstein, Gewirtz & Grossman, LLC
Jun 11, 2026, 10:01 ET Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight
5-HT6 receptor antagonist, represents a non-dopaminergic strategy aimed at stabilizing symptoms through serotonin pathway modulation. Its global Phase III study had reached nearly 50% enrollment by November 2025, and topline findings are expected in Q1/Q2 2027. Meanwhile, Bristol Myers Squibb/Karuna
More news about: DelveInsight Business Research, LLP
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP
On March 13, 2026, Immutep issued a press release "announc[ing] that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial
More news about: Pomerantz LLP
Jun 11, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against BitGo Holdings, Inc. and Certain Officers - BTGO
Defendants' statements regarding, inter alia, BitGo's financial performance and business prospects as a public company lacked a reasonable basis; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and/or failed
More news about: Pomerantz LLP
Jun 11, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Lucid Group, Inc . and Certain Officers - LCID
deliveries of the Lucid Gravity; (ii) the foregoing was likely to, and did, have a material negative impact on the Company's business and financial results; (iii) accordingly, the Defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and
More news about: Pomerantz LLP
Jun 11, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against AeroVironment, Inc. and Certain Officers - AVAV
U.S. Space Force's ongoing efforts to modernize the SCN; (ii) accordingly, Defendants overstated AeroVironment's business and financial prospects; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.On January 20, 2026, AeroVironment announced
More news about: Pomerantz LLP